金吾财讯 | 制药巨头辉瑞(PFE)周三宣布，欧洲委员会(EC)已正式批准其创新疗法 HYMPAVZI®(marstacimab) 扩大适应症。该药物现可用于治疗12岁及以上、体重至少35公斤且伴有抑制物的甲型血友病或乙型血友病患者。据悉，HYMPAVZI是一种抗组织因子途径抑制物(anti-TFPI)，通过靶向人体天然抗凝机制来重新建立凝血平衡，而非传统的因子替代疗法。该药物是欧盟首个且唯一针对伴有或不伴有抑制物的甲/乙型血友病患者的每周一次皮下注射疗法，显著降低了传统静脉注射带来的治疗负担。基于III期BASIS研究数据，与按需治疗相比，HYMPAVZI使患者的年化出血率(ABR)显著降低了93%。长期随访研究显示，治疗53个月后，出血率依然维持在极低水平。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.